We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Experimental Monobody Drug Inhibits Most Mutated RAS Oncogenes

By Gerald M. Slutzky, PhD
Posted on 17 Nov 2016
Print article
Image: The NS1 monobody binds to H-RAS or K-RAS protein and blocks RAS function by disrupting the protein\'s ability to form active molecular pairs (Photo courtesy of Dr. John P. O\'Bryan, University of Chicago).
Image: The NS1 monobody binds to H-RAS or K-RAS protein and blocks RAS function by disrupting the protein\'s ability to form active molecular pairs (Photo courtesy of Dr. John P. O\'Bryan, University of Chicago).
A novel monobody drug candidate was found to effectively block the action of most of the RAS family of proto-oncogenes, which are mutated in nearly 90% of pancreatic cancers and are also highly prevalent in colon cancer, lung cancer, and melanoma.

About a fourth of melanomas are caused by mutations in the N-RAS gene (neuroblastoma RAS viral oncogene homolog), but patients with this type of cancer have had no effective therapeutic options. Furthermore, mutations in the RAS family of proto-oncogenes (comprising H-RAS, N-RAS, and K-RAS) are very common, being found in 20% to 30% of all human tumors.

Investigators at the University of Illinois, Chicago (USA) reported in the November 7, 2016, online edition of the journal Nature Chemical Biology that they had developed NS1, a synthetic binding protein (monobody) that bound with high affinity to both GTP- and GDP-bound states of H-RAS and K-RAS but not N-RAS.

Monobodies are synthetic binding proteins that are constructed using a fibronectin type III domain (FN3) as a molecular scaffold. Monobodies are simple and robust alternative to antibodies for creating target-binding proteins. Monobodies are generated from combinatorial libraries in which portions of the FN3 scaffold are diversified using molecular display and directed evolution technologies. A major advantage of monobodies over conventional antibodies is that monobodies can readily be used as genetically encoded intracellular inhibitors, which means that the researcher can express a monobody inhibitor in a cell of choice by simply transfecting the cell with a monobody expression vector. This is possible due to the unique characteristics of the underlying FN3 scaffold: small (only about 90 residues), stable, easy to produce, and its lack of disulfide bonds makes it possible to produce functional monobodies regardless of the redox potential of the cellular environment, including the reducing environment of the cytoplasm and nucleus. In contrast, most antibodies and antibody fragments depend on disulfide bonds formation and they must be produced under an oxidizing environment.

The investigators reported that NS1 was a potent inhibitor of growth factor signaling and oncogenic H-RAS- and K-RAS-mediated signaling and transformation but did not block oncogenic N-RAS, BRAF (v-Raf murine sarcoma viral oncogene homolog B), or MEK1(Mitogen-activated protein kinase kinase).

NS1 bound the alpha4-beta6-alpha5 region of RAS, which disrupted RAS dimerization and nanoclustering and led to blocking of oncogenic CRAF–BRAF heterodimerization and activation. These results established the importance of the alpha4-beta6-alpha5 interface in RAS-mediated signaling and defined a previously unrecognized site in RAS for inhibiting RAS function.

"We did not look for a drug or specifically for an inhibitor," said senior author Dr. John O'Bryan, associate professor of pharmacology at the University of Illinois, Chicago. "We used monobody technology, a type of protein-engineering technology, to identify regions of RAS that are critical for its function. The beauty of the technology is that when a monobody binds a protein, it usually works as an inhibitor of that protein."

"Development of effective RAS inhibitors represents a "holy grail" in cancer biology," said Dr. O'Bryan. "We now have a powerful tool we can use to further probe RAS function. While future studies and trials are needed before these findings can be leveraged outside the lab, this study provides new insight into how we can potentially inhibit RAS to slow tumor growth."

Related Links:
University of Illinois, Chicago

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Unit-Dose Packaging solution
HLX
New
Human Immunodeficiency Virus Assay
RealLine HIV Quantitative Kit
New
Flu Test
ID NOW Influenza A & B 2

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more